{"entity":{"id":"lumina","kind":"trial","name":"LUMINA","aka":[],"tldr":"LUMINA used tumour biology, not just age, to pick women who can skip breast radiotherapy: with a luminal A profile and endocrine therapy, local recurrence at five years was about two percent.","summary":"LUMINA was a single-arm prospective study of 500 women aged 55 or older with grade 1 or 2 T1N0 luminal A breast cancer (oestrogen and progesterone receptor-positive, HER2-negative, Ki67 of 13.25 percent or less) who had breast-conserving surgery and endocrine therapy and no radiotherapy. Five-year local recurrence was 2.3 percent, 90 percent confidence interval 1.3 to 3.8 (Whelan and colleagues, New England Journal of Medicine 2023;389:612 to 619), supporting biomarker-based omission.","status":"positive","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01791829","url":"https://clinicaltrials.gov/study/NCT01791829"},{"label":"Whelan et al., New England Journal of Medicine 2023;389:612 to 619: omitting radiotherapy after breast-conserving surgery in luminal A breast cancer","url":"https://doi.org/10.1056/NEJMoa2302344"}],"tags":["radiation-wave2"],"related":[],"cancers":["breast-hr-positive","breast-cancer"],"sections":[],"technologies":["active-surveillance"],"targets":[],"drugs":[],"companies":["ocog"],"institutions":[],"pathways":[],"terms":["radiotherapy-omission-early-breast-cancer"],"trials":["calgb-9343","prime-ii"],"people":[],"bottlenecks":[],"keyPapers":["paper-cowan-lancet-oncol","paper-lumina-n-engl-j-med-2023"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01791829","phase":"2","setting":"Women aged 55 or over with small luminal A breast cancer after breast-conserving surgery and endocrine therapy: radiotherapy omitted","sponsor":"Ontario Clinical Oncology Group","result":"5-year local recurrence 2.3% without radiotherapy in luminal A disease.","started":"2013-07","startedType":"actual","yearReported":2023,"enrolled":500,"enrolledBasis":"registry","outcomes":[{"endpoint":"Local recurrence at 5 years","primary":true,"unit":"%","arms":[{"name":"Endocrine therapy, no radiotherapy","n":500,"value":2.3}]}]},"route":"/trials/lumina/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/"}],"company":[{"id":"ocog","kind":"company","name":"Ontario Clinical Oncology Group","route":"/companies/ocog/"}],"term":[{"id":"radiotherapy-omission-early-breast-cancer","kind":"term","name":"Leaving radiotherapy out","route":"/terms/radiotherapy-omission-early-breast-cancer/"}],"trial":[{"id":"calgb-9343","kind":"trial","name":"CALGB 9343","route":"/trials/calgb-9343/"},{"id":"prime-ii","kind":"trial","name":"PRIME II","route":"/trials/prime-ii/"}],"paper":[{"id":"paper-lumina-n-engl-j-med-2023","kind":"paper","name":"Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer","route":"/key-papers/paper-lumina-n-engl-j-med-2023/"},{"id":"paper-cowan-lancet-oncol","kind":"paper","name":"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","route":"/key-papers/paper-cowan-lancet-oncol/"}]}}